ClinicalTrials.gg
Status unknownNCT05170568Updated Nov 1, 2022

PA3-17 Injection Treatment of Adult Patients With CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

A Phase 1 interventional study of T cell injection targeting CD7 chimeric antigen receptor in CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies, sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-11-01.

Sponsored by PersonGen BioTherapeutics (Suzhou) Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This is a Phase I, open-label, dose-escalation clinical study with the primary objective of evaluating the safety and tolerability of PA3-17 injection in adult subjects with CD7-positive relapsed/refractory lymphoid hematologic malignancies. The secondary objectives are as follows: to evaluate the proliferation and in vivo persistence of CD7-targeted chimeric antigen receptor T (CAR-T) cells after injection of PA3-17; to evaluate the proportion of CD7-positive cells in peripheral blood after injection of PA3-17; to preliminarily evaluate the efficacy of PA3-17 injection in adult subjects with CD7-positive relapsed/refractory lymphoid hematologic malignancies; to evaluate the immunogenicity of PA3-17 injection; and to explore the applicable dose in Phase II trial.

Read the detailed description

Approximately 5 sites are planned to be selected for the clinical trial. The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 0.5 × 10\^6, 2.0 × 10\^6 and 4.0 × 10\^6 CAR-T/kg groups in order of sequence. And the subjects will be administered once. Dose escalation will follow 3 + 3 design and 3-6 subjects in each group will complete a single dose. Within the same dose group, the next subject will be administered after the previous subject has completed at least 14 days of safety observation. After the last subject in each dose group has completed the dose-limiting toxicity (DLT) assessment window of 28 days after single dose, the enrollment and treatment for the next dose group may be initiated after the Safety Review Committee (SRC) agrees to enter the next dose group based on clinical safety data assessment.

When DLT occurs in 1 of 3 subjects in a dose group, 3 additional subjects in the same dose group will be required (up to 6 subjects in the dose group have completed DLT assessment): if no DLT occurs in the additional 3 subjects, dose escalation will continue; if 1 of the 3 additional subjects experiences one DLT, dose escalation will be discontinued; if more than 1 of the 3 additional subjects experiences DLTs, dose escalation will be discontinued, and 3 additional subjects will be required to be enrolled at one lower dose level for DLT assessment. After the end of escalation for the maximum dose group, if no MTD is observed, the highest dose level is defined as the MTD.

02

Conditions studied

  • CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies
03

In context

Lead sponsor

PersonGen BioTherapeutics (Suzhou) Co., Ltd. is the lead sponsor of 43 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 70 years old (inclusive), male or female;
  • Expected survival time ≥ 3 months;
  • performance status of 0-1;
  • Malignant lymphoma diagnosed according to WHO2016 criteria: priority will be given to T-cell acute lymphoblastic leukemia/lymphoma (including early pre-T-cell lymphoblastic leukemia);
  • Subjects with recurrent/ T-cell acute lymphoblastic leukemia/lymphoma (including early pre-T-cell lymphoblastic leukemia) who have failed standard treatment or lack effective treatment and meet any of the following criteria:

    1. No remission after at least two courses of standard induction chemotherapy;
    2. Early relapse (\<12 months) after complete remission; Or complete remission followed by late relapse (≥12 months) without remission after a course of standard induction chemotherapy;
    3. Patients who did not achieve remission after two or more ;
    4. Recurrence after hematopoietic stem cell transplantation.
  • Lymphoid hematologic diagnosed as CD7 positive by flow cytometry and/or CD7 positive by histopathological immunohistochemistry at screening, with the positive rate of tumor ≥ 30%;
  • For CD7-positive lymphoid hematologic malignancies involving bone marrow and/or peripheral blood, patients with CD4/CD8 double-negative surface immunophenotype of tumor cells as determined by flow cytometry;
  • Liver, kidney and cardiopulmonary function shall meet the following requirements:

    1. Creatinine ≤ 1.5 ;
    2. ≥ 45%;
    3. Oxygen saturation > 91%;
    4. Total ≤ 2 × ULN; and AST ≤ 2.5 × ULN; for ALT and AST abnormalities due to disease (e.g., liver infiltration or bile duct obstruction) as judged by the investigator, the indicators can be relaxed to ≤ 5 × ULN;
  • Patients who can understand the trial and have signed informed consents.

Exclusion criteria

Exclusion Criteria:

  • Subjects who need to use ;
  • Subjects with malignant tumors other than T-cell hematological within 5 years prior to screening, with the exception of adequately treated cervical carcinoma in situ, basal cell carcinoma or squamous cell carcinoma, localized prostate cancer after radical surgery, and ductal carcinoma in situ after radical mastectomy;
  • Positive for surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood hepatitis B virus (HBV) DNA titer detection not within the normal reference range; positive for virus (HCV) antibody and peripheral blood hepatitis C virus (HCV) RNA; positive for (HIV) antibody; positive for cytomegalovirus (CMV) DNA test; positive for syphilis test;
  • Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure ( [NYHA] classification ≥ III), severe arrhythmia;
  • Unstable systemic diseases judged by the investigator: including but not limited to serious liver, kidney or metabolic diseases requiring drug treatment;
  • Within 7 days prior to screening, there are active or uncontrollable infections requiring systemic therapy (except for mild genitourinary infection and upper respiratory tract infection);
  • Pregnant or lactating women, and female subjects who plan to become pregnant within 2 years after cell infusion or male subjects whose partners plan to become pregnant within 2 years after cell infusion;
  • Subjects who have received CAR-T therapy or other gene-modified cell therapy prior to screening;
  • Subjects who are receiving systemic therapy within 7 days prior to screening or need long-term use of systemic steroid therapy during treatment as judged by the investigator (except for inhalation or topical use);
  • Subjects who have participated in other clinical studies within 3 months prior to screening;
  • Subjects who have evidence of central nervous system invasion at screening;
  • Conditions not eligible for cell preparation as judged by the investigator;
  • Other conditions considered unsuitable for enrollment by the investigator.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    T cell injection targeting CD7 chimeric antigen receptor

    Biological: T cell injection targeting CD7 chimeric antigen receptor

Interventions

  • The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 0.5 × 106, 2.0 × 106 and 4.0 × 106 CAR-T/kg groups in order of sequence. And the subjects will be administered once.

    Also known as: PA3-17 injection

06

What researchers measure

Primary outcomes

  1. DLT

    Dose limiting toxicity

    Time frame: About 2 years

  2. MTD

    Maximum tolerated dose

    Time frame: About 2 years

Secondary outcomes

  1. Assessment of the safety after CD7-targeted chimeric antigen receptor T cells infusion (Safety)

    Number of participants with treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: About 2 years

  2. Assessment of pharmacokinetic (about Cmax)

    Assessment of the highest concentration (Cmax) of CD7-targeted chimeric antigen receptor T cells amplified in peripheral blood after administration.

    Time frame: 28 days

  3. Assessment of pharmacokinetic (about Tmax)

    Assessment of the time to reach the highest concentration (Tmax) of CD7-targeted chimeric antigen receptor T cells in peripheral blood after administration.

    Time frame: 28 days

  4. Assessment of pharmacokinetic (about AUC0-28d)

    Assessment of the area under the curve AUC0-28d after administration.

    Time frame: 28 days

  5. Assessment of pharmacokinetic (about Cmax)

    Assessment of the highest concentration (Cmax) of CD7-targeted chimeric antigen receptor T cells amplified in peripheral blood after administration.

    Time frame: 90 days

  6. Assessment of pharmacokinetic (about Tmax)

    Assessment of the time to reach the highest concentration (Tmax) of CD7-targeted chimeric antigen receptor T cells in peripheral blood after administration.

    Time frame: 90 days

  7. Assessment of pharmacokinetic (about AUC0-90d)

    Assessment of the area under the curve AUC0-90d after administration.

    Time frame: 90 days

  8. PD endpoints

    The proportion and absolute value of CD7-positive cells in peripheral blood at each time point; concentration levels of CAR-T-related serum cytokines such as CRP and IL-6;

    Time frame: About 2 years

  9. To Evaluate Anti-tumour Activity (Overall Survival)

    Defined as the time from start of CD7 CAR-T cell therapy to death (due to any cause);

    Time frame: About 2 year

  10. To Evaluate Anti-tumour Activity (Progression Free Survival)

    Defined as the time from the start of CD7 CAR-T cell therapy to the first disease progression or recurrence or death from any cause.

    Time frame: About 2 year

  11. To Evaluate Anti-tumour Activity (overall response rate)

    Rate of participants who with lymphoma aquire complete response (CR) or partial response (PR) or those who with leukemia CR or CR with incomplete hematologic recovery (CRi).

    Time frame: About 3 months

  12. Immunogenicity endpoints

    Positive rate of human anti-CAR antibody at each time point.

    Time frame: About 2 years

  13. To Evaluate Anti-tumour Activity (duration of response)

    Defined as the time from the first tumor assessment of CR or PR (lymphoma), CR or CRi (leukemia) to the first assessment of disease recurrence or progression or death due to any cause.

    Time frame: About 2 years

07

Study locations

1 of 1 sites recruiting
  • PersonGen.Anke Cellular Therapeutice Co., Ltd.
    Hefei, Anhui 230088, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Dec 2022, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 24, 2021
First posted
Dec 28, 2021
StartActual
Dec 1, 2021
Primary completionEst.
Dec 1, 2022
CompletionEst.
Dec 1, 2024
Last update
Nov 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05170568
Collaborators
The First Affiliated Hospital of Zhengzhou University, Peking University People's Hospital, Wuhan Union Hospital, China, Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences), Zhejiang University
Responsible party
Sponsor
First posted
Dec 28, 2021
Start date
Dec 1, 2021
Primary completion
Dec 1, 2022 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Nov 1, 2022

Study contacts

Mingzhi Zhang, Doctor
Contact
mingzhi_zhang@126.com
037166295562
Xiaojun Huang, Doctor
Contact
xjhrm@medmail.com.cn
+86-13701389625
Mingzhi Zhang, Doctor
principal investigator · The First Affiliated Hospital of Zhengzhou University
Xiaojun Huang, Doctor
principal investigator · Peking University People's Hospital
Heng Mei, Doctor
principal investigator · Wuhan Union Hospital, China
Dehui Zou, Doctor
principal investigator · Hematology Hospital of Chinese Academy of Medical Sciences (Hematology Research Center of Chinese Academy of Medical Sciences)
He Huang, Doctor
principal investigator · Zhejiang University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Autologous Anti-CD7 CAR T Cells PA3-17

Start the discussion